Qianyu Li

Shanghai Key Laboratory For Tumor Microenvironment And Inflammation
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

SUMOylation activates ECHS1 for adaptive catabolism in lung cancer.

SUMOylation activates ECHS1 for adaptive catabolism in lung cancer.

Journal: Cell death & disease

Published: January 05, 2026

Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy.

Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 05, 2024

Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.

Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: May 30, 2024

CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.

CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.

Journal: Cancer letters

Published: March 21, 2024

Pseudouridine synthase 1-targeted therapy activates antiviral immunity to boost cancer immunotherapy.

Pseudouridine synthase 1-targeted therapy activates antiviral immunity to boost cancer immunotherapy.

Journal: Cell reports

Published: June 19, 2023

KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.

KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.

Journal: Clinical and translational medicine

Published: April 25, 2023

Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.

Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.

Journal: Hepatology (Baltimore, Md.)

Published: January 20, 2023

Effects of a Quality Improvement Program to Reduce Central Venous Catheter-Related Infections in Hemodialysis Patients.

Effects of a Quality Improvement Program to Reduce Central Venous Catheter-Related Infections in Hemodialysis Patients.

Journal: The American journal of the medical sciences

Published: March 18, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026